Endre søk
RefereraExporteraLink to record
Permanent link

Direct link
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Annet format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annet språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf
Unfractionated heparin versus bivalirudin in patients undergoing primary percutaneous coronary intervention: a SWEDEHEART study
Uppsala universitet, Medicinska och farmaceutiska vetenskapsområdet, Medicinska fakulteten, Institutionen för medicinska vetenskaper, Kardiologi. Västerås Univ, Dept Cardiol, Västerås, Sweden..
Lund Univ, Skane Univ Hosp, Dept Cardiol, Lund, Sweden..
Lund Univ, Skane Univ Hosp, Dept Cardiol, Lund, Sweden..
Uppsala universitet, Medicinska och farmaceutiska vetenskapsområdet, Medicinska fakulteten, Institutionen för medicinska vetenskaper, Kardiologi. Uppsala universitet, Medicinska och farmaceutiska vetenskapsområdet, Medicinska och farmaceutiska vetenskapsområdet, centrumbildningar mm, Uppsala kliniska forskningscentrum (UCR).
Vise andre og tillknytning
2017 (engelsk)Inngår i: EuroIntervention, ISSN 1774-024X, E-ISSN 1969-6213, Vol. 12, nr 16, s. 2009-2017Artikkel i tidsskrift (Fagfellevurdert) Published
Abstract [en]

Aims: The aim of the stud was to compare outcomes in unfractionated heparin (UM) and bivalirudintreated patients undergoing primary percutaneous coronary intervention (PPCI). Methods and results: This observational study contained 20,612 PPCT patients treated with either GM monotherapv or bivalirudin with or without concomitant UFE. Patients with oral anticoagulant or glycoprotein IIb/IIIa inhibitor (GPI) treatment were excluded. The primary outcome measure was definite early stent thrombosis (Si) that occurred at low and similar rates in UNA only and bivalirudin-treated patients: 0.9% vs. 0.8% (adjusted hazard ratio [HR] 1.08, 95% confidence interval [CI]: 0.7-1.65). All-cause death at 30 days occurred in 6.9% vs. 5.4% of patients (adjusted HR 1.23, 95% Cl: 1.05-1.44) and within 365 days in 12.1% vs. 8.9% (adjusted HR 1.34, 95% CI: 1.19-1.52) in the two groups, respectively. The incidence of major bleeding within 30 days was 0.8% vs. 0.6% (adjusted HR 1.54, 95% CI: 0.97-2.45). The incidence of reinfarction within 365 days and stroke within 30 days was similar between groups. Conclusions: In this large, nationwide observational study we found low and similar rates of early ST in UFH only and bivalirudin-treated patients undergoing primary PCI. Mortality was higher in IJFH compared with bivalirudin-treated patients.

sted, utgiver, år, opplag, sider
2017. Vol. 12, nr 16, s. 2009-2017
Emneord [en]
adjunctive pharmacotherapy, drug-eluting stent, STEMI, stent thrombosis
HSV kategori
Identifikatorer
URN: urn:nbn:se:uu:diva-320667ISI: 000397598300017PubMedID: 28044990OAI: oai:DiVA.org:uu-320667DiVA, id: diva2:1092954
Tilgjengelig fra: 2017-05-04 Laget: 2017-05-04 Sist oppdatert: 2017-05-04bibliografisk kontrollert

Open Access i DiVA

Fulltekst mangler i DiVA

PubMed

Søk i DiVA

Av forfatter/redaktør
Grimfjärd, PerLagerqvist, BoSvennblad, BodilVarenhorst, ChristophJames, Stefan K.
Av organisasjonen
I samme tidsskrift
EuroIntervention

Søk utenfor DiVA

GoogleGoogle Scholar

pubmed
urn-nbn

Altmetric

pubmed
urn-nbn
Totalt: 216 treff
RefereraExporteraLink to record
Permanent link

Direct link
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Annet format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annet språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf